Rhythm Pharmaceuticals (RYTM) Q1 FY26 earnings call

Rhythm Pharmaceuticals reported strong Q1 FY26 results, driven by robust initial uptake of IMCIVREE for acquired hypothalamic obesity (HO) in the U.S. and significant regulatory progress in Europe and Japan. The company is advancing its pipeline, including new formulations and next-generation therapies, while maintaining a solid financial position to support future growth and address unmet needs in rare genetic obesity disorders.